The November 2014 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. The new issue contains a number of new listings:

• Tobramycin (Tobi)
• Fingolimod hydrochloride (Gilenya)
• Natalizumab (Tysabri)
• Rivastigmine (Exelon)
• Nilotinib hydrochloride monohydrate (Tasigna)
• Glycopyrronium bromide (Seebri Breezhaler)
• Indacaterol maleate (Onbrez)
• Deferasirox (Exjade)
• Everolimus (Afinitor)

For more details, go to: http://www.pharmac.govt.nz/2014/10/17/SU.pdf